Other languages Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 am EDT			5-day change	1st Jan Change
21.2 ^HKD	+0.95%		-0.47%	+3.67%

May. 15	China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection	MT
May. 14	China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection	May. 15
China Traditional Chinese Medicine, Sinopharm Update on Privatization Process Status	May. 14
Wall Street Cues, Property Outlooks Lift Asian Stock Markets	Apr. 29
China, Hong Kong stocks rise, led by property shares	Apr. 29
Sinopharm Group Co. Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29
Sinopharm Group Shares Fall as Higher Costs Cut Into Quarterly Profit	Apr. 28
Sinopharm Group's Q1 Profit Falls as Operating Costs Rise	Apr. 28
Central Bank, Tech Outlooks Lift Major Asian Stock Markets	Apr. 26
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	Apr. 16
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	Apr. 10
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	Mar. 27
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue	Mar. 24
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024	Mar. 24
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 24
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings	Mar. 21
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6%	Mar. 21
US Inflation, Light News Flow Churns Asian Stock Markets	Mar. 13
Sinopharm Group Co. Ltd. Announces Change of Registered Address	Mar. 12
Nomura Adjusts Sinopharm Group’s Price Target to HK$32.39 Form HK$33.31, Keeps at Buy	Mar. 11
China Traditional Chinese Medicine's Stock Bolts on Privatization Offer	Feb. 22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Other languages

Filters